CHGA and prostate carcinoma: PPIs have been postulated to reduce the efficacy of upfront DOC treatment by blunting its inhibitory effects on androgen-sensitive human prostate cancer cells [19,20], with elevated chromogranin A levels in CRPC patients [19] and a promotion of cell proliferation and survival in castration-sensitive prostate cancer cell lines [8].